Benign%20prostatic%20hyperplasia Patient Education

Patient Education

Lifestyle Modification

Reduce intake of liquids, particularly before going out in public or before periods of sleep (2 hours before bedtime)
Avoid or reduce intake of caffeinated or alcoholic beverages and spicy foods
Avoid or monitor use of medications such as decongestants, antihistamines, antidepressants, and diuretics
Prevent or treat constipation
Try to achieve and maintain a healthy weight
Exercise pelvic floor muscles (Kegel exercise)
Train the bladder to hold more urine for longer periods
Try to urinate at least once every 3 hours
“Double voiding” may help - after urinating, wait, and try to urinate again
Advise urethral milking to prevent postmicturition dribble
Perform catheter drainage with urinary retention especially if UTI is present

Product Highlight - Lanzotred

13 Sep 2023

Enzalutamide 40 mg softcap

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.